API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://www.prnewswire.com/news-releases/empowerpharm-inc-is-delighted-to-announce-the-outcome-of-their-phase-2-clinical-trial-assessing-cannabidiol-cbd-drug-product-for-social-anxiety-disorder-sad-302165831.html
https://www.globenewswire.com/news-release/2024/04/15/2862708/0/en/London-Research-Pharmaceuticals-presents-the-advancement-of-LRP-661-their-oral-cannabidiol-sulphate-drug-candidate-at-the-prestigious-Epilepsy-Therapies-Diagnostics-Development-ETD.html
https://pharmaphorum.com/news/harmony-buys-cannabidiol-firm-zynerba-200m-deal
https://www.prnewswire.com/news-releases/fda-concludes-that-existing-regulatory-frameworks-for-foods-and-supplements-are-not-appropriate-for-cannabidiol-will-work-with-congress-on-a-new-way-forward-301731634.html
https://www.transopharm.com/blog/transo-pharm-establishes-relationship-with-22nd-century-group-as-their-partner-for-global-sales-marketing-and-distribution-of-pharmaceutical-grade-cannabinoid-apis
https://www.fiercepharma.com/pharma/jazz-pharmaceuticals-sues-generics-makers-over-its-cannabis-derived-epilepsy-drug
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-cannabidiol-oral-solution-25601.pdf
https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-presents-new-findings-caregiver-survey
https://www.fiercepharma.com/pharma/puretech-readies-oral-cbd-capsule-clinic-challenge-jazzs-epidiolex
https://www.globenewswire.com/news-release/2022/11/15/2555997/36775/en/Zynerba-Pharmaceuticals-Announces-European-Commission-Has-Granted-Orphan-Drug-Designation-for-Zygel-in-22q11-2-Deletion-Syndrome.html
https://www.zynerba.com/zynerba-pharmaceuticals-announces-issuance-of-new-u-s-patent-for-zygel-for-the-treatment-of-22q11-2-deletion-syndrome/
https://www.prnewswire.com/news-releases/isosceles-pharmaceuticals-signs-non-binding-letter-of-intent-with-a-strategic-partner-for-phase-1-development-of-its-proprietary-synthetic-cannabidiol-intravenous-product-301662397.html
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-initiation-of-phase-3-trial-evaluating-epidiolexepidyolex-cannabidiol-for-patients-with-epilepsy-with-myoclonic-atonic-seizures-301608430.html
https://www.globenewswire.com/news-release/2022/05/05/2436669/36215/en/InMed-to-Supply-Rare-Cannabinoids-to-Radicle-Science-s-Radicle-Energy-Study-to-Assess-the-Health-Effects-of-THCV.html
https://www.prnewswire.com/news-releases/mgc-pharmaceuticals-enters-partnership-with-sciensus-rare-for-distribution-of-cannabinoids-to-treat-refractory-epilepsy-dementia-and-alzheimers-in-the-eu-and-uk-301517261.html
https://www.accesswire.com/693001/Panacea-Life-Sciences-Inc-Partners-with-European-CBD-Market-Leader-Chanelle-McCoy-Health-for-US-Launch
https://www.accesswire.com/692087/Can-B-Corp-and-American-Development-Partners-Agree-to-Finance-and-Develop-CBD-Lounges
https://www.globenewswire.com/news-release/2022/03/02/2395415/0/en/Artelo-Biosciences-Receives-Notice-of-Allowance-for-Method-of-Use-Patent-in-the-United-States-for-ART12-11-a-Proprietary-Cocrystal-of-Cannabidiol.html
https://www.prnewswire.com/news-releases/brains-bioceutical-initiates-clinical-trial-agreement-to-tackle-opioid-addiction-301478375.html
https://www.accesswire.com/687077/Love-Hemp-Group-PLC-Announces-Directorate-Changes
https://www.prnewswire.com/news-releases/canntab-announces-closing-of-convertible-debenture-private-placement-warrant-expiry-extension-and-corporate-update-301473454.html
https://www.globenewswire.com/news-release/2022/02/01/2376728/0/en/Skye-Bioscience-Reports-Potential-Neuroprotective-Benefit-of-SBI-100-In-Preclinical-Glaucoma-Model.html
https://www.globenewswire.com/news-release/2022/01/19/2369218/36215/en/InMed-Launches-Cannabicitran-CBT-Expanding-its-Rare-Cannabinoid-Portfolio-for-the-Health-and-Wellness-Sector.html
https://www.globenewswire.com/news-release/2022/01/14/2367137/0/en/Avicanna-Enters-Master-Supply-Agreement-with-Chilean-Pharmaceutical-Pioneer-Knop-Laboratorios-S-A.html
https://www.pharmacompass.com/pdf/news/scisparc-issued-us-patent-for-its-core-technology-that-treats-central-nervous-systems-disorders-1643013825.pdf
https://www.globenewswire.com/news-release/2021/12/28/2358591/0/en/MALACHITE-INNOVATIONS-ANNOUNCES-TWO-GRANTED-U-S-PATENTS-AND-NEW-PCT-PATENT-FILING.html
https://www.prnewswire.com/news-releases/vpr-brands-announces-favorable-settlement-of-a-recently-filed-patent-infringement-case-301439466.html
https://www.prnewswire.com/news-releases/cibdol-launches-revolutionary-cbd-oil-formula-301437403.html
https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-present-from-expanding-neuroscience-portfolio-epidiolex-cannabidiol-oral-solution-data-at-the-2021-american-epilepsy-society-annual-meeting-301434871.html
https://www.biospace.com/article/releases/enveric-biosciences-announces-positive-preclinical-data-for-ev102-radiodermatitis-drug-candidate/?s=71
https://www.prnewswire.com/news-releases/aurora-builds-on-a-decade-of-global-leadership-in-plant-genetics-with-the-launch-of-occo-301425002.html
https://www.prnewswire.com/news-releases/aurora-cannabis-announces-fiscal-2022-first-quarter-results-301420228.html
https://www.prnewswire.com/news-releases/curebase-level-announce-clinical-trial-to-determine-whether-cannabinoids-can-help-veterans-sleep-better-301415517.html
https://www.chron.com/news/houston-texas/article/Texas-Delta-8-ban-faces-new-legal-challenge-from-16565882.php
https://www.prnewswire.com/news-releases/nalu-bio-secures-global-supply-chain-to-chemically-synthesize-cbd-301407771.html
https://www.clinicaltrialsarena.com/special-focus/covid-19/cbd-covid-19-cardiol-trial/
https://www.prnewswire.com/news-releases/cannabics-announces-new-corporate-logo-new-website-and-new-company-presentation-301388844.html
https://www.businesswire.com/news/home/20210929005209/en/ANANDA-Scientific-and-David-Geffen-School-of-Medicine-UCLA-Announce-Clinical-Trial-Utilizing-Liquid-StructureTM-Cannabidiol-CBD-for-the-Treatment-of-Opioid-Use-Disorder-OUD
https://www.globenewswire.com/news-release/2021/09/24/2302894/0/en/Avicanna-Files-US-Patent-Application-for-a-Novel-Cannabinoid-Formulation-in-Reducing-Incidence-of-Seizures-and-Sudden-Unexpected-Death-in-Epilepsy.html